Bellicum Pharmaceuticals Inc. appointed William Grossman as chief medical officer, effective Feb. 5.
Most recently, Grossman served as the group medical director of cancer immunotherapy at Genentech Inc., a unit of Roche Holding AG.
Bellicum appoints chief medical officer
A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research
2021 Year in Review: Highlighting Key Investment Banking Trends
Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings
Global M&A By the Numbers: Q3 2021
Bellicum Pharmaceuticals Inc. appointed William Grossman as chief medical officer, effective Feb. 5.
Most recently, Grossman served as the group medical director of cancer immunotherapy at Genentech Inc., a unit of Roche Holding AG.